Showing results (31-40 of 241) with videos related to

Sort By:
Pageof 25
Investigational New Drugs|April 24, 2013
Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumorsAung Naing, Siqing Fu, Ralph G Zinner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2012
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activityJohn Moroney, Siqing Fu, Stacy Moulder, et al.
International Journal of Cancer|September 8, 2016
Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTERIshwaria M Subbiah, Jennifer J Wheler, Kenneth R Hess, et al.
Investigational New Drugs|October 1, 2016
Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experienceManojkumar Bupathi, Joud Hajjar, Stacie Bean, et al.
Cancer Chemotherapy and Pharmacology|October 14, 2010
Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvementApostolia M Tsimberidou, Katherine Letourneau, Siqing Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experienceSiqing Fu, F Diane Barber, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology|January 31, 2016
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancerRabih Said, Yang Ye, David S Hong, et al.
Hepato-Gastroenterology|May 15, 2012
Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosisApostolia M Tsimberidou, Siqing Fu, Ishwaria M Subbiah, et al.
The Oncologist|August 24, 2011
Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experienceHazem El-Osta, David Hong, Jennifer Wheler, et al.
Pageof 25